Puma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $94.48, for a total value of $188,771.04. Following the completion of the transaction, the senior vice president now directly owns 27,246 shares in the company, valued at $2,574,202.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Richard Paul Bryce also recently made the following trade(s):

  • On Monday, July 3rd, Richard Paul Bryce sold 5,000 shares of Puma Biotechnology stock. The stock was sold at an average price of $87.10, for a total value of $435,500.00.

Puma Biotechnology Inc (NYSE PBYI) traded up 1.64% during midday trading on Monday, reaching $95.85. The company had a trading volume of 1,277,640 shares. The firm has a 50-day moving average of $84.95 and a 200-day moving average of $50.35. Puma Biotechnology Inc has a 12 month low of $28.35 and a 12 month high of $97.14. The stock’s market cap is $3.54 billion.

Puma Biotechnology (NYSE:PBYI) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.06) by $0.09. On average, equities analysts expect that Puma Biotechnology Inc will post ($8.43) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Puma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce Sells 1,998 Shares” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/24/puma-biotechnology-inc-nysepbyi-svp-richard-paul-bryce-sells-1998-shares.html.

Several analysts recently weighed in on PBYI shares. Bank of America Corporation restated a “buy” rating and set a $117.00 target price (up previously from $100.00) on shares of Puma Biotechnology in a research note on Friday. Cowen and Company reiterated an “outperform” rating and issued a $120.00 price objective (up previously from $91.00) on shares of Puma Biotechnology in a research report on Saturday. Leerink Swann reissued an “outperform” rating and issued a $125.00 target price (up from $115.00) on shares of Puma Biotechnology in a report on Wednesday, July 19th. Citigroup Inc. reissued a “buy” rating and issued a $105.00 target price on shares of Puma Biotechnology in a report on Friday, June 30th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $105.00 price target on shares of Puma Biotechnology in a report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $101.75.

Hedge funds have recently bought and sold shares of the stock. Creative Planning boosted its stake in shares of Puma Biotechnology by 62.3% in the second quarter. Creative Planning now owns 2,862 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 1,099 shares during the period. Bank of Montreal Can boosted its position in Puma Biotechnology by 1.8% in the second quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 97 shares during the period. Fox Run Management L.L.C. bought a new position in Puma Biotechnology during the second quarter worth about $227,000. Credit Suisse AG boosted its position in Puma Biotechnology by 97.9% in the first quarter. Credit Suisse AG now owns 82,644 shares of the biopharmaceutical company’s stock worth $3,075,000 after buying an additional 40,890 shares during the period. Finally, Redmile Group LLC boosted its position in Puma Biotechnology by 33.7% in the first quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock worth $64,185,000 after buying an additional 435,274 shares during the period. Institutional investors and hedge funds own 80.98% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.